每经AI快讯，医药板块盘初走强，华人健康涨超15%，鹭燕医药、重药控股涨停，达嘉维康、人民同 泰、漱玉平民等跟涨。 每日经济新闻 ...

Market Overview and Sector Characteristics - The Shanghai Composite Index closed up by 1.19%, while the Shenzhen Component Index fell by 2.40%, with the median change in A-shares being an increase of 0.61% [1] - A total of 49 stocks hit the daily limit up, an increase of 7 from the previous day, while 19 stocks hit the limit down, an increase of 4 [2] Industry Characteristics - The sectors with the most limit-up stocks today were communication equipment, specialized equipment, and general equipment [3] - In the communication equipment sector, 5 stocks reached the limit up, driven by accelerated 5G construction and AI computing demand [4] - The specialized equipment sector saw 4 stocks limit up, supported by policy backing and recovering orders [4] - The general equipment sector had 3 stocks limit up, boosted by policy support for equipment upgrades and enhanced manufacturing recovery expectations [4] Concept Characteristics - The most represented concepts among limit-up stocks were optical communication, liquid cooling servers, and consumer sectors [5] - In the optical communication concept, 7 stocks hit the limit up, benefiting from the explosive demand for AI computing and the acceleration of 800G optical module shipments [5] - The liquid cooling server concept also had 7 stocks limit up, as liquid cooling technology becomes the mainstream solution for heat dissipation due to AI computing demand [5] - The consumer sector had 6 stocks limit up, supported by policy stimulus and the year-end consumption peak, with strong expectations for consumer potential [5] Limit-Up Stock List - Among the limit-up stocks, 3 reached historical highs, including Yingweike, Ping An Electric, and Huanxu Electronics [6] - 10 stocks reached near one-year highs, including Shengtong Energy, Jiamei Packaging, and others [7][8] Main Capital Flow - The top 5 stocks with the highest net inflow of main capital among limit-up stocks were Yingweike, Guojiji Heavy Industry, Guangxun Technology, ShenNan Circuit, and Meinian Health [9][10] - The stocks with the highest net inflow as a percentage of market value included Wangzi New Materials, Nanjing Business Travel, and others [10] Continuous Limit-Up Situation - There were 41 first-limit stocks today, with 5 stocks achieving a second limit up and 3 stocks achieving three or more consecutive limit ups [11] - The top 5 stocks with the most consecutive limit ups included Baida Group, Shengtong Energy, and others [11]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002788 证券简称：鹭燕医药 公告编号：2025-028 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、担保情况概述 二、担保进展情况 1、自公司2025年8月26日披露《关于为子公司提供担保的进展公告》（公告编号：2025-021）起至本公 告披露日，公司对子（孙）公司担保进展情况如下： 2、上述担保中，被担保人为公司全资子（孙）公司的，公司依据《鹭燕医药股份有限公司对外担保管 理制度》规定，免除其对公司提供反担保义务。 3、截止本公告披露日，公司对子（孙）公司实际发生的担保余额为424,108.77万元。上述担保额度在公 司股东会批准的额度范围之内。 三、累计对外担保数量及逾期担保的数量 截止本公告披露日，公司累计对外担保总额839,174.73万元，占公司最近一期经审计净资产（2024年 度）的262.91%，实际担保余额为445,976.39万元，占公司最近一期经审计净资产（2024年度）的 139.72%。除子公司成都禾创药业集团有限公司收购前原股东隐瞒的担保外，公司及所属子公司实 ...

关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：002788 证券简称：鹭燕医药 公告编号：2025-028 鹭燕医药股份有限公司 一、担保情况概述 鹭燕医药股份有限公司（以下简称"鹭燕医药"或"公司"）于 2025 年 4 月 20 日、2025 年 5 月 13 日召开公司第六届董事会第五次会议、2024 年年度股东大会审议通过了《关于公 司申请综合授信额度及对子公司担保事项的议案》，同意公司（包括直接和间接控股的子公 司）向各银行或其他金融机构申请总额不超过人民币 220 亿元的综合授信额度，同时公司为 部分子公司申请贷款和采购货款付款提供担保，合计担保授信额度人民币 140 亿元。本次担 保及授权事项期限自公司 2024 年年度股东大会审议通过之日起不超过 12 个月。具体内容请 详见公司于 2025 年 4 月 22 日披露的《关于公司申请综合授信额度及对子公司担保事项的公 告》（公告编号：2025-006）。 二、担保进展情况 1、自公司 2025 年 8 月 26 日披露《关于为子公司提供担保的进展公告》 ...

每日经济新闻 每经AI快讯，12月10日，医药商业板块短线走低，瑞康医药跌超7%，润达医疗、人民同泰、塞力医 疗、鹭燕医药等跟跌。 ...

Core Viewpoint - The stock of Luyuan Pharmaceutical has experienced fluctuations, with a recent decline of 2.03%, while the company shows a year-to-date stock price increase of 22.52% [1][2]. Financial Performance - For the period from January to September 2025, Luyuan Pharmaceutical achieved a revenue of 15.855 billion yuan, representing a year-on-year growth of 2.87%. However, the net profit attributable to shareholders decreased by 14.64% to 220 million yuan [2]. - Cumulatively, the company has distributed 728 million yuan in dividends since its A-share listing, with 369 million yuan distributed over the past three years [3]. Stock Market Activity - As of November 28, the stock price was 9.63 yuan per share, with a market capitalization of 3.741 billion yuan. The trading volume was 35.1211 million yuan, with a turnover rate of 0.95% [1]. - The net outflow of main funds was 4.1611 million yuan, with significant selling pressure observed [1]. Business Overview - Luyuan Pharmaceutical, established on September 3, 2008, and listed on February 18, 2016, is based in Xiamen, Fujian Province. The company primarily engages in the distribution and retail of pharmaceuticals, traditional Chinese medicine, medical devices, and vaccines [1]. - The revenue composition of the company is as follows: pharmaceuticals 83.20%, medical devices 11.54%, traditional Chinese medicine 4.22%, and others 1.05% [1]. Shareholder Information - As of September 30, the number of shareholders was 22,700, a decrease of 3.01% from the previous period, while the average circulating shares per person increased by 3.10% to 16,784 shares [2].

Core Viewpoint - Luyuan Pharmaceutical stated on November 19 that the company discloses the number of shareholders at the end of the period in its regular reports and quarterly reports [2] Group 1 - The company responds to investor inquiries regarding shareholder information disclosure [2]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.92% on November 18, with Yao Yigou leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance - Notable gainers included: - Ren Da Medical (603108) with a closing price of 15.97, up 2.90% and a trading volume of 278,200 shares, totaling 442 million yuan [1] - People's Tongtai (600829) with a closing price of 17.72, up 6.49% and a trading volume of 1,148,700 shares, totaling 1.902 billion yuan [1] - Major decliners included: - Yao Yigou (300937) with a closing price of 33.95, down 6.37% and a trading volume of 115,000 shares, totaling 396 million yuan [2] - Luhua Pharmaceutical (002788) with a closing price of 10.29, down 5.86% and a trading volume of 467,300 shares, totaling 489 million yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 706 million yuan from institutional investors, while retail investors contributed a net inflow of 705 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing while retail investors remained active [2] Individual Stock Capital Flow - Ren Da Medical (603108) had a net inflow of 49.2 million yuan from institutional investors, while retail investors saw a net outflow of 65.5 million yuan [3] - Yao Yigou (300937) experienced a significant net outflow of 560.4 million yuan from institutional investors [3] - The data reflects varying levels of investor confidence across different stocks within the sector [3]

Market Overview - The pharmaceutical commercial sector experienced a decline of 1.62% on November 17, with Luyuan Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers included: - Renmin Tongtai (600829) with a closing price of 16.64, up 9.98% and a trading volume of 768,000 shares, totaling 1.276 billion yuan [1] - Other stocks in the sector showed mixed results, with several companies like Shanghai Pharmaceuticals (601607) and Guoyao Yizhi (000028) experiencing declines of 1.20% and 1.53% respectively [1] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 875 million yuan from institutional investors, while retail investors contributed a net inflow of 674 million yuan [2] - The data indicates that retail investors were more active in the market compared to institutional investors during this period [2] Individual Stock Capital Flow - Key stocks with significant capital flow include: - Shuyuan Pingmin (301017) with a net inflow of 17.85 million yuan from institutional investors, while retail investors had a net outflow of 35.94 million yuan [3] - Nanjing Pharmaceutical (600713) had a net inflow of 17.30 million yuan from institutional investors, but also saw outflows from retail investors [3] - Guoyao Yizhi (000028) and Shanghai Pharmaceuticals (601607) also experienced mixed capital flows, with institutional inflows but retail outflows [3]

Core Viewpoint - The company, Luyan Pharmaceutical, confirmed its involvement in the storage, cold chain transportation, and distribution services for vaccine products, including influenza vaccines, as part of its main business operations [1]. Group 1 - The company primarily engages in the distribution of pharmaceuticals, traditional Chinese medicine pieces, and medical devices [1]. - The main source of revenue for the company is from pharmaceutical wholesale sales [1]. - The company has capabilities that include the storage and distribution of vaccine products [1].